Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy
C. Lyu, Y. Ye, M. Lensing, K.-U. Wagner, R. Weigel, S. Chen
This study shows that blocking Gi/o-GPCR signaling inhibits HER2-driven breast cancer growth and improves HER2-targeted therapy effectiveness.
bioRxiv · Jun 15, 2021Cancer Biology